Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

MYM Completes Architectural Layout and Finalizes Security Plans for Phase One ACMPR Greenhouses at the Weedon, QC Project

MYM Nutraceuticals
Posted on: 31 Jul 17

VANCOUVER, British Columbia, July 31, 2017 /PRNewswire/ --

MYM Nutraceuticals Inc., (CSE: MYM) (OTC: MYMMF), (the "Company" or "MYM ") is extremely pleased to announce the completion of the architectural layout and security plans for phase one ACMPR greenhouses for the Weedon, QC project.

Award winning, Montreal based Latimer Hu Architects have completed plans for 300,000 square feet of greenhouse space. When all five phases are complete, the Weedon, QC project will see 1.5 million square feet of operational greenhouse production space.

Security plans were completed by Tyco Security, international leaders in the security industry.

MYM has now completed all of the Standard Operating Procedures regarding the Quality Assurance Program.

About MYM 

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to the acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD

"Rob Gietl"

Rob Gietl, CEO
MYM Nutraceuticals Inc.
http://www.mymarijuana.ca

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on http://www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

MYM Investor Relations Contact:
Terry Brown - +1(855)696-2261

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 31/07/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.